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Using high- resolution computed tomography to detect 
interstitial lung disease in patients with systemic 
sclerosis: comment on the concise communication by 
Bernstein et al
To the Editor:
We read with interest the concise communication by  Bernstein 
et al (1) regarding practice patterns among rheumatolo gists when 
screening for interstitial lung disease (ILD) in patients with systemic 
sclerosis (SSc). Referencing the study by Suliman et al (2), the au-
thors state that pulmonary function tests (PFTs) are not sensitive or 
specific for detecting ILD in this population. The primary message 
in that study (2) is that PFTs yield a false- negative rate of 62.5% 
for early detection of ILD in SSc when high- resolution computed 
tomography (HRCT) is used as the gold standard. It is important 
to note, however, that the primary measurement used to define 
baseline abnormality in the study by Suliman and colleagues was 
forced vital capacity (FVC) <80% of predicted. As already point-
ed out by Degano et al (3), the incorporation of other measures, 
including diffusing capacity for carbon monoxide (DLco) and pos-
sibly functional residual capacity, improves sensitivity. This was 
documented by Suliman and  colleagues, who found that incor-
porating other measures of pulmonary function, including DLco 
<70% of predicted, increased sensitivity for detecting ILD to 72%.
Although the presence and extent of baseline fibrosis on 
HRCT has been shown to be prognostically valuable in SSc (4), 
a 1992 study by Steen and colleagues also showed that among 
patients with SSc who had normal DLco (defined as ≥80% of pre-
dicted, rather than ≥70% of predicted per the study by Suliman et 
al) at baseline, only 2 of 218 (<0.01%) developed clinically signifi-
cant pulmonary disease after 7.2 years of follow- up (5). This sug-
gests that baseline DLco may be a sensitive indicator of pulmonary 
disease requiring treatment in SSc, although lacking in specificity.
Based on these considerations, we believe it may be pre-
mature to dismiss PFTs as a screening tool for clinically signif-
icant scleroderma lung disease. The significance of HRCT ab-
normalities suggestive of ILD in the absence of alterations in lung 
volumes or gas exchange remains unclear, as is reflected in the 
inconsis tent use of this tool by rheumatologists, as described by 
Bernstein and colleagues.
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Reply
To the Editor:
We thank Drs. Warner and Huston for their interest in 
our concise communication. We agree that PFTs should be 
 considered as a screening tool for clinically significant ILD in 
SSc. However, we disagree that the importance of HRCT abnor-
malities suggestive of ILD is unclear when alterations in lung vol-
umes or gas exchange are absent. Patients with SSc and normal 
PFT parameters can still experience a clinically significant decline 
in their lung function over time. In a retrospective cohort study of 
98 patients with SSc who had mild ILD on baseline HRCT and 
a mean baseline FVC of 102% of predicted, 26% experienced 
a clinically significant decline in lung function at 1- year follow- up 
(1). In the phase II trial of tocilizumab for the treatment of diffuse 
cutaneous SSc, the mean FVC at baseline was 82% of predict-
ed in the control arm, yet 23% of the patients in the control arm 
experienced a 10% decline in FVC over 48 weeks (2). Similar 
findings were reported in the phase III trial by Khanna et al (3).
Moreover, there are data from population- based cohorts 
demonstrating that early, subclinical ILD on HRCT has both 
biologic and clinical relevance for predicting clinical ILD (4,5). 
In community- dwelling adults, subclinical ILD on HRCT is 
 associated with lower FVC, reduced exercise capacity,  elevated 
serum levels of interleukin- 6, and an increased risk of  developing 
clinically evident ILD and ILD- specific mortality at 12- year follow- 
up (4–6).
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PFTs have a critical role in the initial assessment of lung 
function in patients with SSc, and in monitoring lung function 
trajectory. Yet, with its 100% sensitivity (it is the gold standard 
for ILD detection) and the availability of modern technology that 
can deliver radiation doses as low as 0.15 mGy (7), HRCT has 
substantial advantages. Further research into the clinical impact 
of HRCT screening for ILD in patients with SSc will allow for the 
development of clear, data- driven recommendations to inform 
practicing rheumatologists.
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